AI Tool Comparison
Recursion vs Aidoc
An objective side-by-side comparison based on global rankings, AI scores, and monthly user data.
Higher ranked
Recursion
HealthcareAI-enabled drug discovery platform.
AI Score72.5 / 100
#271
Global rank
–
Monthly users
VS
Aidoc
HealthcareAI platform for radiology and clinical workflow.
AI Score52.4 / 100
#802
Global rank
–
Monthly users
Side-by-Side Comparison
| Recursion | Aidoc | |
|---|---|---|
| Category | Healthcare | Healthcare |
| Global Rank | #271 | #802 |
| AI Score | 72.5/100 | 52.4/100 |
| Monthly Users | – | – |
| Pricing | Contact Sales | Contact Sales |
| Website | recursion.com | aidoc.com |
Pros & Cons
Recursion
- Large pipeline after the Exscientia merger
- Public reporting
- Cash runway into early 2028
- No approved drug yet
- Large net losses against small revenue
- Details come mostly from secondary sources
Aidoc
- Large set of FDA-cleared acute indications
- Foundation model approach lets it add indications faster
- Strong funding ($500M+ total)
- Governance tools through aiOS
- No public pricing
- Clearance counts vary between sources
- Some abdominal triage submissions were still under FDA review